Skip to main content
. Author manuscript; available in PMC: 2023 Nov 14.
Published in final edited form as: Cancer Cell. 2022 Nov 14;40(11):1358–1373.e8. doi: 10.1016/j.ccell.2022.10.017

Table 2:

Highest grade toxicity experienced on treatment for n=51 patients. AEs grade 2+ in at least 10% of patients and all grade 4+.

Worst grade
Total N=51 2 - Moderate 3 - Severe 4 - Life Threatening 5 - Fatal

Upper respiratory infection 22 (43) 21 (41) 1 (2) - -
Fatigue 21 (41) 18 (35) 3 (6) - -
Hypophosphatemia 21 (41) 2 (4) 16 (31) 3 (6) -
Neutropenia 15 (29) 2 (4) 12 (24) 1 (2) -
Lymphocytopenia 14 (27) 3 (6) 11 (22) - -
Hyperglycemia 12 (24) 9 (18) 2 (4) 1 (2) -
Constipation 10 (20) 9 (18) 1 (2) - -
Cytopenia 10 (20) 8 (16) 2 (4) - -
Diarrhea 10 (20) 8 (16) 2 (4) - -
Anemia 8 (16) 7 (14) 1 (2) - -
Lung infection 8 (16) 3 (6) 5 (10) - -
Hypertension 7 (14) 4 (8) 3 (6) - -
Insomnia 7 (14) 6 (12) 1 (2) - -
Thrombocytopenia 7 (14) 4 (8) 2 (4) 1 (2) -
Rash maculopapular 6 (12) 4 (8) 2 (4) - -
Cataract 1 (2) - - 1 (2) -
Cholecystitis 1 (2) - - 1 (2) -
Diabetic ketoacidosis 1 (2) - - 1 (2) -
Lymphocytosis 1 (2) - - 1 (2) -
Myocardial infarction 1 (2) - - - 1 (2)
Sepsis 1 (2) - - - 1 (2)